Physician profile
Edward Suarez
NPI 1285697524
$8,208.80
in general payments reported to CMS, 2019-2025
33 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $1,851 · 2021: $1,362 · 2022: $1,883 · 2023: $1,219 · 2024: $572 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,908.76 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $915.43 | 2019-2022 | |
| Lilly USA, LLC | $706.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $700.86 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.96 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $528.68 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $497.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $328.49 | 2021-2025 | Ubrelvy |
| Nestle Healthcare Nutrition INC. | $302.14 | 2020-2023 | |
| Exact Sciences Corporation | $279.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $249.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $237.41 | 2019-2020 | |
| Esperion Therapeutics, INC. | $122.00 | 2021-2022 | |
| Pfizer INC. | $102.71 | 2019-2024 | |
| Smith+Nephew, INC. | $88.30 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $61.12 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $60.91 | 2021-2024 | |
| Genentech USA, INC. | $56.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $54.03 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.41 | 2019-2020 | |
| Astellas Pharma US INC | $41.12 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $40.39 | 2020 | |
| Allergan, INC. | $36.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $36.52 | 2022 | |
| Zyla Life Sciences, INC. | $31.96 | 2019 | |
| Eisai INC. | $31.54 | 2020 | |
| Arbor Pharmaceuticals, INC. | $28.98 | 2020-2021 | |
| Forte Bio-Pharma LLC | $28.76 | 2023 | Prolate, Nalocet |
| Ethicon US, LLC | $23.15 | 2020 | |
| Radius Health, INC. | $16.26 | 2020 | |
| Phadia US INC. | $15.79 | 2020 | |
| Corcept Therapeutics | $15.73 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.